+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer



Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer



Cancer Science 106(11): 1554-1560



This study evaluated the prognostic value of positron emission tomography/computed tomography (PET/CT) using (18) F-fluoroazomycin arabinoside (FAZA) in patients with advanced non-small-cell lung cancer (NSCLC) compared with (18) F-fluorodeoxyglucose (FDG). Thirty-eight patients with advanced NSCLC (stage III, 23 patients; stage IV, 15 patients) underwent FAZA and FDG PET/CT before treatment. The PET parameters (tumor-to-muscle ratio [T/M] at 1 and 2 h for FAZA, maximum standardized uptake value for FDG) in the primary lesion and lymph node (LN) metastasis and clinical parameters were compared concerning their effects on progression-free survival (PFS) and overall survival (OS). In our univariate analysis of all patients, clinical stage and FAZA T/M in LNs at 1 and 2 h were predictive of PFS (P = 0.021, 0.028, and 0.002, respectively). Multivariate analysis also indicated that clinical stage and FAZA T/M in LNs at 1 and 2 h were independent predictors of PFS. Subgroup analysis of chemoradiotherapy-treated stage III patients revealed that only FAZA T/M in LNs at 2 h was predictive of PFS (P = 0.025). The FDG PET/CT parameters were not predictive of PFS. No parameter was a significant predictor of OS. In patients with advanced NSCLC, FAZA uptake in LNs, but not in primary lesions, was predictive of treatment outcome. These results suggest the importance of characterization of LN metastases in advanced NSCLC patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637453

Download citation: RISBibTeXText

PMID: 26292100

DOI: 10.1111/cas.12771


Related references

PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. Journal of Nuclear Medicine 54(8): 1175-1180, 2013

Prognostic value of PET/CT with (18)F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy. Annals of Nuclear Medicine 30(3): 217-224, 2015

Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 141(3): 563-568, 2015

Advanced Lung Cancer Inflammation Index, a New Prognostic Score, Predicts Outcome in Patients With Small-Cell Lung Cancer. Clinical Lung Cancer 16(6): E165-E171, 2016

The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy. Journal of ChemoTherapy 27(1): 35-39, 2015

Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Supportive Care in Cancer 23(6): 1699-1708, 2015

Prognostic Significance of Modified Advanced Lung Cancer Inflammation Index (ALI) in Patients with Small Cell Lung Cancer_ Comparison with Original ALI. Plos One 11(10): E0164056-E0164056, 2016

Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology 6(2): 286-290, 2011

Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respiratory Medicine 98(4): 357-362, 2004

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. Journal of Clinical Oncology 13(5): 1221-1230, 1995

Analysis of prognostic factors in 541 female patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 14(3): 245-250, 2011

Prognostic factors in older patients with advanced non-small cell lung cancer in China. Tumori 100(1): 69-74, 2014

Prognostic value of serum CA125 level in patients with advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 22(1): 30-31, 2002

Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer. Lung Cancer 90(3): 375-380, 2016

A laboratory prognostic index model for patients with advanced non-small cell lung cancer. Plos One 9(12): E114471-E114471, 2015